Leonard Zehr, Author at BioTuesdays

This Week's Feature

CymaBay laser focused on seladelpar pivotal trial for PBC

After resolving a delay in its biliary cholangitis (PBC) program, CymaBay Therapeutics (NASDAQ:CBAY) is activating clinical sites in North America and Europe, and recruiting patients in its global RESPONSE registration...

June 15, 2021

Features

Clene pioneering therapeutic nanocatalysts to improve cellular bioenergetics

Clene (NASDAQ:CLNN) is developing a novel approach for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease, using nanocatalysts in order to...

June 8, 2021

Features

Cognetivity Neurosciences tackling dementia when it counts

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF) is using artificial intelligence to enable early detection of cognitive decline in neurodegenerative disorders, such as dementia and Alzheimer’s disease, the leading...

June 1, 2021

Features

Gregory Penner takes us into the world of aptamers

As president, a co-founder and CEO of closely-held NeoVentures Biotechnology, Gregory Penner, Ph.D., took a different route developing aptamers for healthcare solutions. His training was in quantitative genetics of crop...

May 25, 2021

Features

Azura Ophthalmics taking dermatological approach to ocular surface diseases

Closely-held Azura Ophthalmics is developing the first ophthalmic keratolytics for the treatment of lid margin diseases, such as Meibomian gland dysfunction (MGD), blepharitis, dry eye disease and contact lens...

May 18, 2021

Features

MiMedx’s proprietary tissue technology utilizing amniotic tissue as a platform for regenerative medicine

MiMedx Group (NASDAQ:MDXG) is forging ahead with its corporate turnaround as an industry leader in advanced wound care. “As a pioneer in amniotic tissue biologics, we have both a core business, focused on addressing the...

May 11, 2021

Features

TransMedics redefining what’s possible in organ transplantation

TransMedics Group (NASDAQ:TMDX) is transforming the standard of care in solid organ transplants in order to increase the number of organ transplants and improve clinical outcomes.

May 4, 2021

Features

Stuart Long outlines InfoBionic remote cardiac arrhythmia monitoring benefits

As CEO of InfoBionic, a closely-held digital health company with an initial focus on cardiac arrhythmia detection and monitoring, Stuart Long knows his way around achieving commercial growth in the medical device market...

April 27, 2021

Features

ViaCyte developing stem cell-derived islet replacement for diabetes

Closely-held ViaCyte, a company with two decades of experience, is utilizing pluripotent stem cell technology and novel delivery approaches to address multiple disease areas, with an initial focus and lead products...

April 20, 2021

Features

Cyclacel translating cancer biology into potential medicines

Cyclacel (NASDAQ:CYCC) is developing several innovative therapies that target various phases of cell cycle control for the treatment of solid tumor and blood-borne cancers, such as leukemia.

April 13, 2021

Author - Leonard Zehr

CymaBay laser focused on seladelpar pivotal trial for PBC

Clene pioneering therapeutic nanocatalysts to improve cellular bioenergetics

Cognetivity Neurosciences tackling dementia when it counts

Gregory Penner takes us into the world of aptamers

Azura Ophthalmics taking dermatological approach to ocular surface diseases

MiMedx’s proprietary tissue technology utilizing amniotic tissue as a platform for regenerative medicine

TransMedics redefining what’s possible in organ transplantation

Stuart Long outlines InfoBionic remote cardiac arrhythmia monitoring benefits

ViaCyte developing stem cell-derived islet replacement for diabetes

Cyclacel translating cancer biology into potential medicines

General

More